TY - JOUR
KW - Age Factors
KW - Buprenorphine, Naloxone Drug Combination/adverse effects/therapeutic use
KW - Evidence-Based Medicine
KW - Female
KW - Health Status
KW - Humans
KW - Methadone/adverse effects/therapeutic use
KW - Narcotic Antagonists/adverse effects/therapeutic use
KW - Opioid-Related Disorders/drug therapy/therapy
KW - Patient Preference
KW - Primary Health Care/methods
KW - Risk Factors
KW - Risk Reduction Behavior
KW - Social Environment
KW - Young Adult
AU - A. Srivastava
AU - M. Kahan
AU - M. Nader
A1 - 
BT - Canadian family physician Medecin de famille canadien
C5 - Opioids & Substance Use; Education & Workforce
CP - 3
CY - Canada
IS - 3
JF - Canadian family physician Medecin de famille canadien
PP - Canada
PY - 2017
SN - 1715-5258; 0008-350X
SP - 200
EP - 205
EP - 
T1 - Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
T2 - Canadian family physician Medecin de famille canadien
TI - Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
U1 - Opioids & Substance Use; Education & Workforce
U2 - 28292795
VL - 63
VO - 1715-5258; 0008-350X
Y1 - 2017
ER -